DAiP: Multicenter, Randomized, Comparative and Prospective Study Evaluating the Impact on the Care Path of an Editorial Program Accompanied by Advance Directives in Psychiatry (DAP) for People Suffering From Schizophrenia, Bipolar I Disorder or Schizoaffective Disorder

Sponsor
Assistance Publique Hopitaux De Marseille (Other)
Overall Status
Completed
CT.gov ID
NCT03630822
Collaborator
(none)
399
1
2
36
11.1

Study Details

Study Description

Brief Summary

Severe mental illness is accompanied by cognitive fluctuations that can alter decision-making skills and lead to coerced care. Taking into account, on the one hand, the health, social and economic impact of forced hospitalization, on the other hand the importance of self-determination, the reinforcement of the power to act in the evolution of these disorders, new strategies to better reflect the views of people have been developed.

Among these, the drafting of Advanced Directives in Psychiatric (ADP), allows people with mental disorders to write while their decision-making skills are restored care instructions in case of decompensation.

It is a tool of "advanced therapeutic education" and early prevention of relapses.

It is hypothesized that the implementation of drafting accompanied by advance directives to people with severe psychiatric disorders decreases in the short term the number of forced hospitalization care pathway of these people, compared to the subjects having not benefited from this device.

This research will take the form of a randomized controlled trial on 3 sites. The "quantitative" evaluation component of results and processes will be completed with a qualitative anthropological and socio-political evaluation component documenting the trajectories of individuals and the implementation of the program, as well as a "participatory research" component aimed at a dialogue between users, researchers and professionals.

The patient who is a beneficiary of the "Advanced Directives in Psychiatric" program will be encouraged to complete the " Advanced Directives in Psychiatric" document and will receive support in drafting them. The non-beneficiary patient of the program will follow up with his psychiatrist unchanged.

The experimental design of the quantitative component is based on an experimental, randomized, prospective, controlled, parallel study, comparing two groups of subjects with severe psychiatric disorders.

This research will assess the effectiveness, efficiency and impact of the " Advanced Directives in Psychiatric" program compared to conventional psychiatric care alone.

Ultimately, the objective of describing the effects of the program on health organizations and on the representations and practices of professionals, caregivers and users is at the service of a better understanding of the conditions of possibility of the generalization of this experimentation.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Psychiatric Advanced Directive
  • Behavioral: Standard care
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
399 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Experimentation of a Protocol of Psychiatric Advance Directives: Randomized Controlled Multi-site Trial
Actual Study Start Date :
Jan 2, 2019
Actual Primary Completion Date :
May 10, 2021
Actual Study Completion Date :
Jan 2, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: beneficiary of the advance directive program

Behavioral: Psychiatric Advanced Directive
The patient completes a questionnaire to express in advance his wishes regarding his future care in psychiatry.

Active Comparator: beneficiary of standard Support

Behavioral: Standard care
standardized maintenance with the patient

Outcome Measures

Primary Outcome Measures

  1. Rate of patients with compulsory admission [12 months]

    Evaluation of the hospitalization rate by comparing the two groups

Secondary Outcome Measures

  1. Evaluation of patient recovery rates [12 months]

    The rate is assessed by the Recovery Assessment Scale (RAS)

  2. Evaluation of the empowerment rate [12 months]

    The rate is assessed by the Empowerment Scale (ES)

  3. Measuring the health-related quality of life of patients [12 months]

    Health-related quality of life is measured using a specific scale: the S-QOL. It is a self-reported instrument of 41 items that assesses the quality of life in patients with schizophrenia

  4. Measuring mental health symptoms of patients [12 months]

    Mental health symptoms are measured by Modified Colorado Symptom Index (MCSI)

  5. Evaluation of the therapeutic alliance between the patient and his psychiatrist [12 months]

    The therapeutic alliance between the patient and his psychiatrist is assessed by the 4-Point Alliance Self Report (4-PAS) questionnaire

  6. Measuring Disease Awareness [12 months]

    Disease Awareness is assessed by the évaluée par l'échelle SUMD (Scale to Assess Unawareness in Mental Disorder

  7. Evaluation of the severity of the psychiatric disorder by the psychiatrist [12 months]

    The severity of the psychiatric disorder is assessed by the Clinical Global Impression (ICG) scale

  8. Medico-economic analysis (cost-utility) [12 months]

    Number of inpatient

  9. Medico-economic analysis (cost-utility) [12 months]

    Number of emergency department visits

  10. Medico-economic analysis (cost-utility) [12 months]

    Number of outpatient visits

  11. Medico-economic analysis (cost-utility) [12 months]

    Loss of productivity

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • over 18 years old;

  • diagnosed with schizophrenia, bipolar I disorder, or schizoaffective disorder

  • receiving ambulatory care by a treating psychiatrist, investigator

  • having been hospitalized under duress at least once during the year preceding the inclusion

  • being in decision-making jurisdiction

  • can be under curator

  • agreeing to participate in the study and with informed consent signed by the subject, as well as by the legal representative in the case of a person under guardianship.

Exclusion Criteria:
  • less than 18 years old;

  • participating in another study simultaneously

  • in situations of decision-making incompetence

  • not able to read and write

  • refusing to participate in the study, or the legal representative refusing to participate in the study in the case of a person under guardianship.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Assistance Publique Hôpitaux de Marseille Marseille France 13354

Sponsors and Collaborators

  • Assistance Publique Hopitaux De Marseille

Investigators

  • Study Director: Jean-Olivier ARNAUD, Director, Assistance Publique Hôpitaux de Marseille

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Assistance Publique Hopitaux De Marseille
ClinicalTrials.gov Identifier:
NCT03630822
Other Study ID Numbers:
  • 2018-04
  • 2018-A00146-49
First Posted:
Aug 15, 2018
Last Update Posted:
Mar 31, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 31, 2022